WO2008093848A1 - ホスファチジルコリンを含有する炎症マーカー低減組成物 - Google Patents

ホスファチジルコリンを含有する炎症マーカー低減組成物 Download PDF

Info

Publication number
WO2008093848A1
WO2008093848A1 PCT/JP2008/051680 JP2008051680W WO2008093848A1 WO 2008093848 A1 WO2008093848 A1 WO 2008093848A1 JP 2008051680 W JP2008051680 W JP 2008051680W WO 2008093848 A1 WO2008093848 A1 WO 2008093848A1
Authority
WO
WIPO (PCT)
Prior art keywords
phosphatidylcholine
composition
inflammation marker
liposome
disclosed
Prior art date
Application number
PCT/JP2008/051680
Other languages
English (en)
French (fr)
Inventor
Atsushi Ishikado
Kazuko Yamane
Hiromichi Imanaka
Taketoshi Makino
Original Assignee
Sunstar Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunstar Inc. filed Critical Sunstar Inc.
Priority to JP2008556205A priority Critical patent/JPWO2008093848A1/ja
Publication of WO2008093848A1 publication Critical patent/WO2008093848A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

　炎症マーカーの増大により引き起こされる身体機能の不全を予防又は改善し、メタボリックシンドロームや疾患リスクの発生を低減させ、健康を維持又は増進する経口又は口腔用の医薬品、機能性食品および口腔用組成物を提供する。 　大豆由来のホスファチジルコリンを、好ましくは１位又は２位のいずれか１つ以上に不飽和脂肪酸、特にリノール酸又はリノレン酸が結合したホスファチジルコリンを使用してカプセル剤、錠剤、液剤に配合する。ホスファチジルコリンは好ましくはリポソームの形態にする。さらにω３系不飽和脂肪酸をリポソーム又はリピッドマイクロスフェアに内包する。
PCT/JP2008/051680 2007-02-02 2008-02-01 ホスファチジルコリンを含有する炎症マーカー低減組成物 WO2008093848A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008556205A JPWO2008093848A1 (ja) 2007-02-02 2008-02-01 ホスファチジルコリンを含有する炎症マーカー低減組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007024241 2007-02-02
JP2007-024241 2007-02-02

Publications (1)

Publication Number Publication Date
WO2008093848A1 true WO2008093848A1 (ja) 2008-08-07

Family

ID=39674151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051680 WO2008093848A1 (ja) 2007-02-02 2008-02-01 ホスファチジルコリンを含有する炎症マーカー低減組成物

Country Status (2)

Country Link
JP (1) JPWO2008093848A1 (ja)
WO (1) WO2008093848A1 (ja)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100653A2 (en) 2009-02-02 2010-09-10 Laila Nutraceuticals Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
JP2012031135A (ja) * 2010-06-29 2012-02-16 Kao Corp フルクトース誘導性疾患の予防又は改善剤
WO2012102364A1 (ja) * 2011-01-27 2012-08-02 サンスター株式会社 多価不飽和脂肪酸含有組成物
US8703215B2 (en) 2009-08-04 2014-04-22 Laila Nutraceuticals Agents from Ficus hispida for the amelioration of metabolic syndrome and related diseases
JP2015000853A (ja) * 2013-06-14 2015-01-05 日油株式会社 歯肉炎予防剤
CN104288464A (zh) * 2014-10-17 2015-01-21 李晓丽 一种治疗心脑血管疾病的中药
JP2015174860A (ja) * 2014-03-18 2015-10-05 サンスター株式会社 オーラルケア組成物
CN105288100A (zh) * 2014-07-30 2016-02-03 陈立云 一种专治阻塞肺气肿的中药组合物
US9345732B2 (en) 2009-11-19 2016-05-24 Laila Nutraceuticals Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
WO2016185816A1 (ja) * 2015-05-18 2016-11-24 不二製油グループ本社株式会社 ＩＬ－１β産生抑制作用を有する食品添加用組成物
JP2017527614A (ja) * 2014-09-02 2017-09-21 ブピンダー シン 重水素化又は非重水素化分子及び医薬製剤
JP2018115179A (ja) * 2018-03-16 2018-07-26 サンスター株式会社 オーラルケア組成物
JP2019531309A (ja) * 2016-10-19 2019-10-31 サインパス ファルマ, インク.Signpath Pharma, Inc. チャネル病を引き起こす薬物に対するｄｍｐｃ、ｄｍｐｇ、ｄｍｐｃ／ｄｍｐｇ、ｌｙｓｏｐｇ及びｌｙｓｏｐｃの防御効果
JP2021500318A (ja) * 2017-10-19 2021-01-07 サインパス ファルマ, インク.Signpath Pharma, Inc. チャネル病を引き起こす薬物に対するｄｍｐｃ、ｄｍｐｇ、ｄｍｐｃ／ｄｍｐｇ、ｌｙｓｏｐｇ及びｌｙｓｏｐｃの防御効果
CN113575824A (zh) * 2021-08-25 2021-11-02 上海英库商务咨询有限公司 用于预防ii型糖尿病人群代谢综合征的固体饮料
US11806401B2 (en) 2016-04-27 2023-11-07 Signpath Pharma, Inc. Prevention of drug-induced atrio-ventricular block
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61112020A (ja) * 1984-10-10 1986-05-30 エルヴイラ　ピストレツシ− 抗血栓性並びに抗動脈硬化性高活性を有する薬剤的又は栄養的組成物
JPS62116516A (ja) * 1985-11-18 1987-05-28 Nippon Oil & Fats Co Ltd レシチン組成物及びその製造法
JPH04169525A (ja) * 1990-11-01 1992-06-17 Nissei Marine Kogyo Kk 血清脂質改善機能を有する組成物
JPH09176005A (ja) * 1995-12-21 1997-07-08 Sigma Tau Ind Farmaceut Riunite Spa オメガ−３系のポリ不飽和脂肪酸を併用するｌ−カルニチンまたはアルカノイル ｌ−カルニチン含有医薬組成物
JP2001002565A (ja) * 1999-06-08 2001-01-09 Crinos Ind Farmacobiolog Spa カチオン性リポソームとポリデオキシリボヌクレオチドとの複合体
WO2003022288A1 (fr) * 2001-09-07 2003-03-20 Meiji Dairies Corporation Compositions nutritionnelles permettant de reguler le niveau de glucose sanguin
JP2006298913A (ja) * 2005-03-25 2006-11-02 Lion Corp 歯周組織破壊の抑制・改善剤及びスクリーニング方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61112020A (ja) * 1984-10-10 1986-05-30 エルヴイラ　ピストレツシ− 抗血栓性並びに抗動脈硬化性高活性を有する薬剤的又は栄養的組成物
JPS62116516A (ja) * 1985-11-18 1987-05-28 Nippon Oil & Fats Co Ltd レシチン組成物及びその製造法
JPH04169525A (ja) * 1990-11-01 1992-06-17 Nissei Marine Kogyo Kk 血清脂質改善機能を有する組成物
JPH09176005A (ja) * 1995-12-21 1997-07-08 Sigma Tau Ind Farmaceut Riunite Spa オメガ−３系のポリ不飽和脂肪酸を併用するｌ−カルニチンまたはアルカノイル ｌ−カルニチン含有医薬組成物
JP2001002565A (ja) * 1999-06-08 2001-01-09 Crinos Ind Farmacobiolog Spa カチオン性リポソームとポリデオキシリボヌクレオチドとの複合体
WO2003022288A1 (fr) * 2001-09-07 2003-03-20 Meiji Dairies Corporation Compositions nutritionnelles permettant de reguler le niveau de glucose sanguin
JP2006298913A (ja) * 2005-03-25 2006-11-02 Lion Corp 歯周組織破壊の抑制・改善剤及びスクリーニング方法

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010100653A2 (en) 2009-02-02 2010-09-10 Laila Nutraceuticals Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
US8703215B2 (en) 2009-08-04 2014-04-22 Laila Nutraceuticals Agents from Ficus hispida for the amelioration of metabolic syndrome and related diseases
US9345732B2 (en) 2009-11-19 2016-05-24 Laila Nutraceuticals Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
JP2012031135A (ja) * 2010-06-29 2012-02-16 Kao Corp フルクトース誘導性疾患の予防又は改善剤
KR101771063B1 (ko) * 2011-01-27 2017-08-24 선스타 가부시키가이샤 다가 불포화 지방산 함유 조성물
JP6137836B2 (ja) * 2011-01-27 2017-05-31 サンスター株式会社 多価不飽和脂肪酸含有組成物
US8940312B2 (en) 2011-01-27 2015-01-27 Sunstar Inc. Composition containing polyunsaturated fatty acid
JPWO2012102364A1 (ja) * 2011-01-27 2014-06-30 サンスター株式会社 多価不飽和脂肪酸含有組成物
WO2012102364A1 (ja) * 2011-01-27 2012-08-02 サンスター株式会社 多価不飽和脂肪酸含有組成物
JP2017114895A (ja) * 2011-01-27 2017-06-29 サンスター株式会社 多価不飽和脂肪酸含有組成物
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
JP2015000853A (ja) * 2013-06-14 2015-01-05 日油株式会社 歯肉炎予防剤
JP2015174860A (ja) * 2014-03-18 2015-10-05 サンスター株式会社 オーラルケア組成物
CN105288100A (zh) * 2014-07-30 2016-02-03 陈立云 一种专治阻塞肺气肿的中药组合物
JP2017527614A (ja) * 2014-09-02 2017-09-21 ブピンダー シン 重水素化又は非重水素化分子及び医薬製剤
CN104288464A (zh) * 2014-10-17 2015-01-21 李晓丽 一种治疗心脑血管疾病的中药
JP6103143B1 (ja) * 2015-05-18 2017-03-29 不二製油株式会社 ＩＬ−１β産生抑制作用を有する食品添加用組成物
WO2016185816A1 (ja) * 2015-05-18 2016-11-24 不二製油グループ本社株式会社 ＩＬ－１β産生抑制作用を有する食品添加用組成物
US11806401B2 (en) 2016-04-27 2023-11-07 Signpath Pharma, Inc. Prevention of drug-induced atrio-ventricular block
JP2019531309A (ja) * 2016-10-19 2019-10-31 サインパス ファルマ, インク.Signpath Pharma, Inc. チャネル病を引き起こす薬物に対するｄｍｐｃ、ｄｍｐｇ、ｄｍｐｃ／ｄｍｐｇ、ｌｙｓｏｐｇ及びｌｙｓｏｐｃの防御効果
JP2021500318A (ja) * 2017-10-19 2021-01-07 サインパス ファルマ, インク.Signpath Pharma, Inc. チャネル病を引き起こす薬物に対するｄｍｐｃ、ｄｍｐｇ、ｄｍｐｃ／ｄｍｐｇ、ｌｙｓｏｐｇ及びｌｙｓｏｐｃの防御効果
JP2018115179A (ja) * 2018-03-16 2018-07-26 サンスター株式会社 オーラルケア組成物
CN113575824A (zh) * 2021-08-25 2021-11-02 上海英库商务咨询有限公司 用于预防ii型糖尿病人群代谢综合征的固体饮料

Also Published As

Publication number Publication date
JPWO2008093848A1 (ja) 2010-05-20

Similar Documents

Publication Publication Date Title
WO2008093848A1 (ja) ホスファチジルコリンを含有する炎症マーカー低減組成物
WO2011060945A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
WO2014005013A3 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2012091523A3 (en) Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
WO2011018501A3 (en) Composition including an unsaponifiable fraction
JP2015503593A5 (ja)
WO2010032140A3 (en) Pharmaceutical compositions and related methods of delivery
WO2012021107A3 (en) A liposomal formulation for ocular drug delivery
WO2011101866A3 (en) Gastric retention formulation containing baclofen
HRP20240115T1 (hr) Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
WO2007122635A3 (en) Controlled release formulation comprising anti-epileptic drugs
WO2008000731A3 (en) Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
WO2010092450A8 (en) Stable pharmaceutical composition for atherosclerosis
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
MY160652A (en) Pharmaceutical composition for oral administration
WO2011060944A3 (en) Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
IN2014CN03214A (ja)
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF
RS52735B (en) APPLICATION OF A COMBINATION CONTAINING L-CARNITINE OR ALKANOIL L-CARNITINE, OIL-SOLUBLE OIL-BENZOQUINON AND OMEGA-3-POLYESATURATED FATTY ACID FOR PREPARATION OF NUTRITION OR MEDICINAL PRODUCTS
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
ES2666836T3 (es) Formulaciones homogéneas que comprenden ácidos grasos poliinsaturados omega-3 (n-3 PUFA) y resveratrol para administración oral
de la Lastra Commentary on'Resveratrol commonly displays hormesis: Occurrence and biomedical significance'by Calabrese et al
WO2013057569A3 (en) Extended release pharmaceutical composition containing amoxicillin and clavulanic acid
EP1949900A3 (en) Controlled release solid formulation for oral administration as single dose sachet and method of preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08710712

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008556205

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08710712

Country of ref document: EP

Kind code of ref document: A1